Vismodegib

维莫地吉

Report date: 2026/05/12 20:00:17
NMEFirst In Class

Base Information

Drug NameVismodegib
Drug Alias Name维莫德吉vismodegibvismodegibumErivedgeGDC-0449 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSmoothened receptor antagonists
TargetsSmoothened receptor
Therapy Area/IndicationsSolid tumoursChondrosarcoma, Extraskeletal MyxoidCentral Nervous System Lymphoma +[54] 
Global Approved IndicationsCarcinoma, Basal Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/01/30
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenentech IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteGenentech IncRoche Registration Gmbh
Inactive CompaniesRoche Pharma AgStanford UniversityThe University Of Arizona +[7] 
Active IndicationsSolid tumoursHematologic NeoplasmsMultiple Myeloma +[9] 
Inactive IndicationsChondrosarcoma, Extraskeletal MyxoidCentral Nervous System LymphomaGraft vs Host Disease +[45] 

Other Information

ATC CodeL01XJ01
Related LinksWikipediaDrugBankKEGG